Articles from QuantHealth

QuantHealth, an AI-powered drug development platform trusted by the largest pharmaceutical companies, today announced registration has opened for its annual AI in Clinical Development Summit, which will take place in New York on May 8th. In its second year, the Summit will welcome more than 100 attendees and bring together thought leaders from across healthcare who are shaping the next-generation clinical development to discuss AI's latest advancements and real-world applications in the pharmaceutical industry.

QuantHealth, an AI-powered drug development platform, today announced the appointment of Sharon Dagan as Chief Architect and Siwar El Assad as Chief Information Security Officer, seeing through its end-to-end vision of a clinical AI operating system that covers the entire value chain of clinical trials from target to approval.

QuantHealth, an AI-powered drug development platform, announced today its partnership with Atropos Health, a leader in translating clinical data into high-quality, personalized, real-world evidence for care. QuantHealth will leverage Atropos Health’s federated data model of more than 300 million patient records to strengthen its trial outcome predictions and bring life-saving therapies to patients faster, improving point-of-care solutions.

QuantHealth, an AI-powered clinical trial design company, announced it has surpassed 100 successfully simulated clinical trials, achieving 85 percent accuracy and significant return on investment (ROI) for pharmaceutical partners. The company leverages proprietary technology and patient-centric solutions to resolve the pervasive issue of trial failures. Historically, 90 percent of clinical trials fail due to suboptimal protocol design, inefficiencies, and safety concerns. With drug development taking 10 to 15 years and costing nearly $1 billion per drug, most candidates fail to reach approval. To address these challenges, QuantHealth's Clinical-Simulator forecasts individual patient responses within clinical trials, enabling design teams to anticipate overall trial dynamics and adjust strategies accordingly.

QuantHealth, the leading AI-driven clinical trial design company, today announced a partnership with OMNY Health, the premier healthcare ecosystem for facilitating compliant cross-industry health data sharing. This collaboration aims to unlock novel insights from OMNY Health's vast network of de-identified data, fostering new opportunities for clinical trials, evidence-based practice, and medical research for QuantHealth’s customers, which include four out of the five largest pharmaceutical companies globally.

QuantHealth, an AI-powered clinical trial design company, today is welcoming over 100 attendees for their first AI in Clinical Development Summit, slated to be the cornerstone of innovation in the biotechnology industry. This Summit is set to bring together thought leaders from various sectors of the healthcare ecosystem to explore the transformative potential of artificial intelligence in revolutionizing drug development.

QuantHealth, an AI-powered clinical trial design company, today announced the formation of its inaugural Advisory Board. Founding members Michel Vounatsos, former CEO of Biogen, Rob Scott, former Chief Medical Officer for AbbVie, and Christian Hein, former VP, Global Head of Digital Transformation & Innovation Execution at Novartis, will bring their decades of pharmaceutical experience to provide strategic guidance to QuantHealth. The board members will help support the development and deployment of the company’s core platform services to propel the greater life sciences sector forward.

QuantHealth, an AI-powered clinical trial design company that simulates clinical trials, today announced the appointment of Dr. Adam Petrich, MD, as the company’s inaugural Chief Medical Officer and Adam Goldberger as Chief Financial Officer.

QuantHealth, an AI-powered clinical trial design company that simulates clinical trials, today announced it has received a strategic investment from Accenture Ventures along with participation from a leading CRO firm and additional investors. The new capital brings the total A round amount to $17M and will enable QuantHealth to enhance its platform used by pharmaceutical and biotech companies to save millions on clinical trials and drug development.

QuantHealth, an AI-powered clinical trial design startup, today announced a major product upgrade to its platform to simulate trials at scale and expedite, de risk and optimize drug development. The new product release, Katina, provides clinical researchers with an AI-guided workflow that simulates hundreds of thousands of potential trial protocol combinations of patient groups, treatment parameters and different endpoints, to maximize the trial success probability, while taking into account additional operational and commercial considerations.

QuantHealth, an AI-powered clinical trial design startup, today announced that it has raised a $15 million Series A funding round co-led by Bertelsmann Investments and Pitango HealthTech, with participation from existing investors Shoni Top Ventures and Nina Capital. Previous investors include Boston Millennia Partners, Atooro Fund, and Renegade Ventures. QuantHealth has received $20M in external funding to date.

QuantHealth, an AI-powered clinical trial design startup, today announced the appointment of David Dornstreich as Chief Commercial Officer and General Manager of U.S. Operations. Dornstreich is a life sciences veteran with more than 30 years of experience in life-sciences, and has held C-Suite and executive roles at ConcertAI, ASCO’s CancerLinQ, Dr. Evidence, and Allscripts, where he led multi-million dollar deals and a series of mergers and acquisitions. Dave will work closely with the executive leadership at QuantHealth to scale the business globally and oversee business development and operations in the US.